306 related articles for article (PubMed ID: 31570267)
21. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
22. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
25. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
29. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
Lim EA; Gunther JE; Kim HK; Flexman M; Hibshoosh H; Crew K; Taback B; Campbell J; Kalinsky K; Hielscher A; Hershman DL
Breast Cancer Res Treat; 2017 Apr; 162(3):533-540. PubMed ID: 28190249
[TBL] [Abstract][Full Text] [Related]
30. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Liedtke C; Cardone L; Tordai A; Yan K; Gomez HL; Figureoa LJ; Hubbard RE; Valero V; Souchon EA; Symmans WF; Hortobagyi GN; Bardelli A; Pusztai L
Breast Cancer Res; 2008; 10(2):R27. PubMed ID: 18371219
[TBL] [Abstract][Full Text] [Related]
32. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
34. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
[TBL] [Abstract][Full Text] [Related]
38. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
[TBL] [Abstract][Full Text] [Related]
39. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
40. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
